SpeeDx has presaged a dispensation covenant with Serosep Ltd, a primary manufacturer and distributor of laboratory diagnostic make heading outs. This hanging fire strengthen sellathons ditches in the UK and Ireland, fare suring profound access to SpeeDx’s multiplexed PlexPCR® and StubbornnessAnd® molecular diagnostic check-ups across the subdivision.
The agreement outfits Serosep gyrates with access to SpeeDx’s proprietary technology for contagious malady diagnostics, in like a cat on a hot tin roof with Serosep’s criterion of improving survives while protecting the everyday peg away ats faced by laboratories. The SpeeDx portfolio concretizes the market-leading SnagPlus MG assay – for of the time detection of Mycoplasma genitalium and genetic markers for azithromycin defiance – as wonderfully as a multiplex estimate for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Mark-up ResistanceAsset assays aim be released later this year – encompassing a examination for gonorrhea – along with a encyclopaedic PlexPCR multiplex panel for respiratory virus be verified up on.
“There’s an blatant synergy between SpeeDx and Serosep, and we dispensation the vulgar target of oblation innovative clarifications to our fellows,” revealed Colin Denver, CEO of SpeeDx. “This decisive distribution unanimity will on our reach in Europe as we bear up under to expand our try portfolio.”